Status:
COMPLETED
Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study
Lead Sponsor:
University of Ljubljana
Collaborating Sponsors:
Novartis
General and Teaching Hospital Celje
Conditions:
Multiple Sclerosis
Multiple Sclerosis Lesion
Eligibility:
All Genders
18-65 years
Brief Summary
The study proposal focuses on multiple sclerosis (MS), a chronic incurable disease of the central nervous system (CNS). The MS disease is characterised by recurrent transient disability progression, q...
Eligibility Criteria
Inclusion
- persons diagnosed with MS (any phenotype; according to the 2010 McDonald criteria) and CIS patients
- availability of at least two MRI exams with both FLAIR and T1-weighted scans of the same participant over a period of at least 6 months at the most recent examination
- availability of demographic, clinical data and treatment information for the same participant over a period of at least 6 months at the most recent examination
- availability of EDSS score and at least one previous EDSS scores for the same participant over a period of at least 6 months at the most recent examination
Exclusion
- other clinically relevant systemic diseases if the researcher considers them to be significant
Key Trial Info
Start Date :
December 13 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
654 Patients enrolled
Trial Details
Trial ID
NCT05426980
Start Date
December 13 2021
End Date
September 30 2023
Last Update
December 5 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University medical center Ljubljana
Ljubljana, Osrednjeslovenska, Slovenia, 1000
2
General and teaching hospital Celje
Celje, Slovenia, 3000
3
General hospital Izola
Izola, Slovenia
4
University medical center Maribor
Maribor, Slovenia, 2000